PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Advanced Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: MEN1611|DRUG: Eribulin
Sponsor: MedSIR
Collaborators: Menarini Group